Correlations between negative symptoms and peripheral G protein levels in mononuclear leukocytes of deficit and nondeficit schizophrenics

Abstract. Receptor-coupled G proteins were measured in mononuclear leukocytes (MNL) of 17 drug-treated patients with deficit schizophrenia (DS) and 16 drug-treated patients with nondeficit schizophrenia (NDS). No significant difference was found in MNL levels of Gαs, Gαi, Gαq and Gβ proteins between the two groups; however, MNL levels of Gαs were inversely correlated to the severity of negative symptoms in DS patients, while MNL levels of Gαq were positively correlated to negative symptoms in NDS patients. Since Gαs and Gαq are coupled to D-1 and 5-HT2 receptors, respectively, these findings may support the hypothesis that a prevalent dysfunction of D-1 receptors is involved in the pathophysiology of negative symptoms in DS, whereas a prevalent dysfunction of 5-HT2 receptors underlies negative symptoms in NDS. These results must be regarded as preliminary because of the possible interference of antipsychotic drugs on the explored parameters.

[1]  H. Manji.  G proteins: implications for psychiatry. , 1992, The American journal of psychiatry.

[2]  S. Kanba,et al.  Schizophrenic patients with deficit syndrome have higher plasma homovanillic acid concentrations and ventricular enlargement , 1995, Biological Psychiatry.

[3]  M. Bell,et al.  Memory and executive function impairments in deficit syndrome schizophrenia , 2001, Psychiatry Research.

[4]  R. Buchanan,et al.  Stability of the diagnosis of deficit syndrome in schizophrenia. , 1999, The American journal of psychiatry.

[5]  G. Sedvall,et al.  Chemical brain anatomy in schizophrenia , 1995, The Lancet.

[6]  H. Möller.  Atypical neuroleptics: a new approach in the treatment of negative symptoms , 1999, European Archives of Psychiatry and Clinical Neuroscience.

[7]  F. Okada.  G Proteins in the Medial Temporal Lobe in Schizophrenia , 1997 .

[8]  E. Daneluzzo,et al.  Historical, psychopathological, neurological, and neuropsychological aspects of deficit schizophrenia: a multicenter study. , 2002, The American journal of psychiatry.

[9]  O. Shirakawa,et al.  Isotype-Specific G Protein Abnormalities in the Left Superior Temporal Cortex and Limbic Structures of Patients with Chronic Schizophrenia , 1998, Biological Psychiatry.

[10]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[11]  R. Buchanan,et al.  Neuropsychological impairments in deficit vs nondeficit forms of schizophrenia. , 1994, Archives of general psychiatry.

[12]  S. Avissar,et al.  Elevated dopamine receptor-coupled Gs protein measures in mononuclear leukocytes of patients with schizophrenia , 2001, Schizophrenia Research.

[13]  G. Kaplan,et al.  Differential effects of treatment with typical and atypical antipsychotic drugs on adenylyl cyclase and G proteins , 1999, Neuroscience Letters.

[14]  W. Carpenter,et al.  Deficit and nondeficit forms of schizophrenia: the concept. , 1988, The American journal of psychiatry.

[15]  Robert W. Buchanan,et al.  The schedule for the deficit syndrome: An instrument for research in schizophrenia , 1989, Psychiatry Research.

[16]  O. Shirakawa,et al.  G Protein Abnormalities in Schizophrenia , 1997 .

[17]  P. Kalivas,et al.  Chronic haloperidol does not alter G protein α-subunit levels in rats , 1993 .

[18]  Niels G. Waller.  The Scale for the Assessment of Negative Symptoms , 1995 .

[19]  H. Möller.  Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia , 2001, European Archives of Psychiatry and Clinical Neuroscience.

[20]  G. Simpson,et al.  A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS , 1970, Acta psychiatrica Scandinavica. Supplementum.

[21]  S. Dollfus,et al.  Plasma 3-Methoxy-4-Hydroxyphenylglycol and Homovanillic Acid Measurements in Deficit and Nondeficit Forms of Schizophrenia , 1998, Biological Psychiatry.

[22]  R. Buchanan,et al.  Oculomotor abnormalities and their clinical correlates in schizophrenia. , 1989, Psychopharmacology bulletin.

[23]  K. Bohmaker,et al.  Chronic Treatment with Antipsychotic Drugs Does not Alter G Protein α or β Subunit Levels in Rat Brain , 1996, Neuropharmacology.

[24]  W. Dixon,et al.  BMDP statistical software , 1983 .

[25]  J. Krystal,et al.  Serotonin Receptors as Targets of Antipsychotic Medications , 2000 .

[26]  H. Meltzer,et al.  Selective Increases in Phosphoinositide Signaling Activity and G Protein Levels in Postmortem Brain from Subjects with Schizophrenia or Alcohol Dependence , 1998, Journal of neurochemistry.

[27]  M. Iyo,et al.  Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET , 1997, Nature.

[28]  W T Carpenter,et al.  Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. , 1992, Archives of general psychiatry.

[29]  Robert Paul Liberman,et al.  Training and quality assurance with the Brief Psychiatric Rating Scale: "The drift busters." , 1993 .

[30]  S. Dollfus,et al.  A comparison of plasma homovanillic acid in the deficit and nondeficit subtypes of schizophrenia , 1994, Biological Psychiatry.